ReShape Lifesciences (NASDAQ:RSLS) Releases Quarterly Earnings Results

ReShape Lifesciences (NASDAQ:RSLS) issued its quarterly earnings data on Friday. The medical device company reported ($1.89) earnings per share for the quarter, Zacks reports. ReShape Lifesciences had a negative net margin of 86.36% and a negative return on equity of 179.83%.

ReShape Lifesciences Stock Performance

Shares of RSLS stock opened at $0.46 on Friday. ReShape Lifesciences has a 12-month low of $0.34 and a 12-month high of $29.00. The firm has a 50 day moving average price of $1.59 and a two-hundred day moving average price of $4.02.

About ReShape Lifesciences

ReShape Lifesciences Inc provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.